Clinical trials: PCNSL, open to volunteers
Lymphoma, Primary Central Nervous System Lymphoma
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects.
- Trial name
- NCT06475235
- Testing
- Pembrolizumab, Methotrexate, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Primary CNS Lymphoma
Diagnosis; Objective RespOnse; THErApy
Thi is a prospective and low-intervention clinical trial. We propose to design a panel of "core" genetic alterations by sequencing Cerebral Spinal Fluid (CSF) DNA in patients with confirmed or suspicious Primary Central Neurvous…
- Trial name
- DOROTHEA (NCT05036564)
- Testing
- Lumbar puncture
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- IRCCS San Raffaele
Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
This is a prospective, open-label, multicenter, randomized controlled study in treatment-naive patients with primary central nervous system lymphoma (PCNSL, DLBCL type).
- Trial name
- RM-MA-PD1 (NCT07764601)
- Testing
- Penpulimab, Rituximab, Methotrexate
- Where
- 5 sites in China
- Volunteers
- 58 people
- Sponsor
- WEI XU
Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
This is a multicenter, open-label, single-arm, prospective clinical study of PD-1 inhibitor combined with rituximab, methotrexate, and orelabrutinib (PD-1i+RMO) in the treatment of newly diagnosed primary central nervous system…
- Trial name
- NCT07410520
- Testing
- PD -1/PD-L1 monoclonal antibody, Rituximab (R), Methotrexate
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Primary CNS Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
This clinical study aims to evaluate the tolerability, safety, and efficacy of Anbal-cel in patients with recurrent or refractory PCNSL or SCNSL.
- Trial name
- NCT07062627
- Testing
- Anbal-cel
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Hyungwoo Cho
Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
Efficacy of Lenalidomide Maintenance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma: a Phase II, Open-label, Single-arm Study
Therefore, we intend to conduct a phase II study to evaluate the efficacy of maintenance therapy with lenalidomide as the maintenance therapy for patients with PCNSL or PVRL who have achieved CR or partial response after…
- Trial name
- NCT05901324
- Testing
- intensity-modulated radiotherapy (IMRT)
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
CNS Lymphoma
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
This will be an open-label, single-arm, national phase 1/2 therapeutic study to evaluate the safety, tolerability, and preliminary efficacy of [90Y]Y-PentixaTher ([90Y]Y-PTT) for the treatment of recurrent or refractory primary…
- Trial name
- NCT06132737
- Testing
- [90Y]Y-PentixaTher
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Pentixapharm AG
Primary Central Nervous System (CNS) Lymphoma
CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)
This is an international, prospective, multicenter trial with the aim of characterizing circulating tumor DNA (ctDNA) for early response assessment in PCNSL patients treated with standard of care (SOC) 1st line therapy with a…
- Trial name
- CAPCI (NCT06755619)
- Where
- 5 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Nordic Lymphoma Group
Primary Central Nervous System Lymphoma
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment…
- Trial name
- NCT06175000
- Testing
- Cognitive Assessment, Obinutuzumab, Quality of Life Assessment
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- Providence Health & Services
Primary Central Nervous System Lymphoma (PCNSL)
Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
This project aims to establish and prospectively register a longitudinal, multimodal biobank for primary central nervous system lymphoma (PCNSL).
- Trial name
- CLIMB (NCT07842835)
- Testing
- High-dose methotrexate-based therapy, Bruton tyrosine kinase inhibitor-based therapy
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Xiaohui Ren
Large B-cell Lymphoma, Central Nervous System Lymphoma
Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
This research study is for people who have been diagnosed with large B-cell lymphoma of the central nervous system (CNS), which has either returned or is not responding to current treatment.
- Trial name
- NCT07608731
- Testing
- Golcadomide, Pemetrexed, Rituximab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allison Winter
Central Nervous System Lymphoma
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study.
- Trial name
- NCT05698147
- Testing
- Selinexor, Rituximab, Methotrexate
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Tong Chen, MD
DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
This prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly…
- Trial name
- NCT07749365
- Testing
- hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Pirtobrutinib, Sintilimab
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
This is a prospective, single-Arm, phase II clinical study evaluating the efficacy and safety of thiotepa in combination with pirtobrutinib (a BTK Inhibitor) and sintilimab (a PD-1 Inhibitor) for frail or relapsed/refractory…
- Conditions
- Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma
- Trial name
- NCT07416890
- Testing
- Thiotepa, Pirtobrutinib , Sintilimab(TPS)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhejiang Cancer Hospital
Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
This is a phase Ⅱ clinical study of Zanubrutinib(Z) in combination with methotrexate (M) and thiotepa(T) in treating newly diagnosed primary CNS lymphoma (PCNSL).
- Trial name
- NCT06646211
- Testing
- Zanubrutinib , Thiotepa, Methotrexate , Thiotepa and Zanubrutinib, ASCT±Zanubrutinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
- Conditions
- Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma
- Trial name
- NCT06116110
- Testing
- Long-term Follow-Up
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Miltenyi Biomedicine GmbH
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people…
- Conditions
- Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05681195
- Testing
- Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baptist Health South Florida
Central Nervous System Lymphoma
Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
Subjects who met the inclusion/exclusion criteria were included in the experimental group after signing the informed consent form. One course of Z(R)-MTX(TMZ) treatment was given.
- Trial name
- Zillion (NCT07405255)
- Testing
- Zanubrutinib + Rituximab + MTX ± Selinexor
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Ruijin Hospital
Primary Central Nervous System Lymphoma
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
It is a single arm, multicenter, phase 2 study to explore the efficacy and safety study of OR-MTX chemotherapy（Orelabrutinib, Rituximab and Methotrexate）as first-line regimens in the treatment of newly diagnosed primary central…
- Trial name
- NCT05600660
- Testing
- Orelabrutinib, Rituximab, Methotrexate
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Primary CNS Lymphoma, Brain Lymphoma
Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
Primary central nervous system lymphoma (PCNSL) is an uncommon disease. Conventional treatment has consisted of either whole-brain radiation therapy (WBRT) or methotrexate (MTX)-based combined modality therapy integrating…
- Trial name
- NCT04006561
- Testing
- A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Chang Gung Memorial Hospital